New treatment approach for prostate cancer using RNA regulation
Official title: Regulation of RNA Decapping and Degradation: A novel approach to prostate cancer therapy
Funded at Vortex Biotechnology Corporation · NIH-10758110 · Data updated 2026-11-12
This study is testing a new treatment called VBT-34 that helps fight advanced prostate cancer by speeding up the destruction of harmful RNA in cancer cells, especially for patients who haven't had success with other therapies.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vortex Biotechnology Corporation NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $397,168 |
| NIH project number | 1R43CA281394-01A1 |
| Project ID | NIH-10758110 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer who have experienced treatment failure with standard therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not yet undergone standard treatment may not benefit from this research.
What this research studies
This research focuses on developing a novel small molecule that regulates RNA destruction to treat prostate cancer, particularly in cases where standard therapies have failed. The approach involves blocking specific proteins that inhibit RNA decapping, which is crucial for the destruction of cancer-related RNAs. By enhancing RNA degradation, the treatment aims to reduce cancer cell growth and invasion, potentially improving outcomes for patients with advanced prostate cancer. The research includes laboratory experiments to test the effectiveness of the new compound, VBT-34, in inhibiting cancer progression.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for men with advanced prostate cancer who have not responded to existing therapies.
How similar studies have gone: While the approach of targeting RNA regulation is innovative, similar strategies in cancer treatment have shown promise, indicating potential for success.
Where this research is happening
-
Vortex Biotechnology Corporation
Charleston, United States Active
Researchers
- Principal investigator: Kraft, Andrew S — Vortex Biotechnology Corporation
- Study coordinator: Kraft, Andrew S
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.